CARs with humanized single chain variable fragment (scFv) regions entered clinical trials in 2016, when the first 100% human-derived anti-CD19 CAR (HuCAR-19) was administered to nine patients with advanced NHL [53]. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.